*direkter Zusammenhang mit Labor
2007
Belyanskaya, L.L., Marti, T.M., Hopkins-Donaldson, S., Kurtz, S., Felley-Bosco, E., Stahel, R.A. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol. Cancer, 6:66. 2007.*
Opitz, I., Sigrist, B., Hillinger, S., Lardinois, D., Stahel, R., Weder, W, Hopkins-Donaldson, S. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma cells. Lung Cancer, 56: 327-336. 2007.*
Ziegler, A., Seemayer, C.A., Hinterberger, M., Vogt, P., Bigosch, C., Gautschi, O., Tornillo, L., Betticher, D.C., Moch, H., Stahel, R.A. Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results. Lung Cancer, 57:282-291. 2007.*
Weder, W., Stahel, R.A., Bernhard, J., Bodis, S., Vogt, P., Ballabeni, P., Lardinois, D., Jermann, M., Betticher, D., Schmid, R., Stupp, R., Ris, H.-B., Mingrone, W., Roth, A.D., Spiliopoulos, A. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol., 18; 1196-1202. 2007.
Weiss, G.J., Rosell, R., Fossella, F., Perry, M., Stahel, R., Barata, F., Nguyen, B., Paul, S., McAndrews, P., Hanna, N., Kelly, K., Bunn, P.A. The impact of induction chemotherapy on the outcome of second-line therapy with Pemetrexed or Docetaxel in patients with advanced non-small-cell lung cancer. Ann. Oncol., 18:453-460. 2007.
Filipits, M., Haddad, V., Schmid, K., Huynh, A., Dunant, A., André, F., Brambilla, E., Stahel, R., Pignon, J.P., Soria, J.C., Popper, H.H., Le Chevalier, T., Pirker, R. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: InternationalAdjuvant Lung Cancer Trial Biologic Program. Clin. Cancer. Res. 13:3892-3898. 2007.
Filipits, M., Pirker, R., Dunant, A., Lantuejoul, S., Schmid, K., Huynh, A., Haddad, V., André, F., Stahel, R., Pignon, J.P., Soria, J.C., Popper, H.H., Le Chevalier, T., Brambilla, E. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J. Clin. Oncol., 25:2735-2740. 2007.
De Feraudy, S., Limoli, C.L., Giedzinski, E., Karentz, D., Marti, T.M., Feeney, L., Cleaver, J.E., Pol eta is required for DNA replication during nucleotide deprivation by hydroxyurea. Oncogene, 26;5713-5721. 2007.
Pavlidis, N., Vermorken, J., Stahel, R., Bernier, J., Cervantes, A., Audisio, R., Pentheroudakis, G., Costa, A. Oncology for medical students. A European School of Oncology contribution to undergraduate cancer education. Cancer Treat. Rev., 33:419-426. 2007.
Pavlidis, N., Hansen, H., Stahel, R. ESMO clinical recommendations: a practical guide for medical oncologists. Ann. Oncol., 18:1759-63. 2007.
Junker, K., Lindner, M., Schütte, W., Stahel, R. Diagnostik und Therapie des Pleuramesothelioms. Onkologie, 30:1-5. 2007.
Stahel, R.A. Adenocarcinoma, a molecular perspective. Ann. Oncol., 18 Suppl 9:ix147-149. 2007.
2008
Belyanskaya, L.L., Hopkins-Donaldson, S., Kurtz, S., Simon, H.-U., Stahel, R., Zangemeister-Wittke, U. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer, 60:355-265, 2008.*
D’Addario, G., Rauch, D., Stupp, R., Pless, M., Stahel, R., Mach, N., Jost, L., Widmer, L., Tapia, C., Bihl, M., Mayer, M., Ribi, K., Lerch, S., Bubendorf, L., Betticher, D.C. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann. Oncol., 19:739-45, 2008.
Ribi, K., Bernhard, J., Schuller, J.C., Weder, W., Bodis, S., Jörger, M., Betticher, D., Schmid, R., Stupp, R., Ris, H.-B., Stahel, R.A., Swiss Group for Clinical Cancer Research SAKK. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: Feasibility and responsiveness to clinical changes. Lung Cancer, 61:398-404, 2008.
Santoro, A., O’Brien, M.E., Stahel, R.A., Nackaerts, K., Baas, P., Karthaus, M., Eberhardt, W., Paz-Ares, L., Sundstrom, S., Liu, Y., Ripoche, V., Blatter, J., Visseren-Grul, C.M., Manegold, C. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J. Thorac. Oncol., 3:756-63, 2008.
Stahel, R.A., Weder, W., Felip, E., ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol., 19 (Suppl. 2):ii43-44, 2008.
Pentheroudakis, G., Stahel, R.A., Hansen, H., Pavlidis, N. Heterogeneity in cancer guidelines: should we eradicate or tolerate? Ann. Oncol., 19:2067-78, 2008.
Stahel, R.A. Educational book of the 33rd ESMO Congress Stockholm, Sweden 12-16 September 2008. Introduction. Ann Oncol., 19 (Suppl 7):vii22, 2008.
Rosell, R., Manegold, C., Moran, T., Garrido, P., Blanco, R.M., Lianes, P., Stahel, R., Trigo, J.M., Wei, J., Taron, M. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer. Clinical Lung Cancer, 9:S76-S82, 2008.
Diezi, J., Felley-Bosco, E. Precis de toxicologie / [Jacques Diezi et al.]. Editions Médecine & Hygiéne, Genéve, 2008.
2009
Ampollini, L., Soltermann, A., Felley-Bosco, E., Lardinois, D., Arni, S., Speck, R.F., Weder, W., Opitz, I. Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting. Eur. J. Cardiothorac. Surg. 35:457-62. 2009.*
Stahel, R.A., Felley-Bosco, E., Opitz, I., Weder, W. Malignant pleural mesothelioma. Future Oncol. 5:391-402. 2009.*
Stahel, R.A., Weder, W. Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach? Curr Opin Oncol. 21:124-130. 2009.*
Weder, W., Opitz, I., Stahel, R. Multimodality strategies in malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 21:172-176. 2009.*
Carteni, G., Manegold, C., Martin Garcia, G., Siena, S., Zielinski, C.C., Amadori, D., Liu, Y., Blatter, J., Visseren-Grul, C., Stahel, R. Peritoneal mesothelioma – Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 64:211-218, 2009.
Stupp, R., Mayer, M., Kann, R., Weder, W., Zouhair, A., Betticher, D.C., Roth, A.D., Stahel, R.A., Majno, S.B., Peters, S., Jost, L., Furrer, M., Thierstein, S., Schmid, R.A., Hsu-Schmitz, S.F., Mirimanoff, R.O., Ris, H.B., Pless, M. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol. 10:785-793. 2009.
Audisio, R.A., Stahel, R.A., Aapro, M.S., Costa, A., Pandey, M., Pavlidis, N. Successful publishing: How to get your paper accepted. Surg. Oncol. 18:350-356. 2009.
Pavlidis, N., Hansen, H., Stahel, R. ESMO clinical recommendations: using the easier and faster approach to oncology guidelines. Ann. Oncol. 20 Suppl 4:7-9. 2009.
Stahel, R.A., Weder, W., Felip, E. ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20 Suppl 4:73-75. 2009.
Stahel, R., Felley-Bosco, E., Opitz, I., Weder, W. Mesothelioma, In: Lung Cancer Therapy Annual 6. Edited by Heine H Hansen. Informa Healthcare USA, Inc., New York 2009, pp205-222
2010
Reck, M., Stahel, R.A., von Pawel, J., Karthaus, M., Korfee, S., Serke, M., Schuette, W.H., Eschbach, C., Fink, T.H., Leschinger, M.I., Manegold, C. Pemetrexed in the treatment of malignant mesothelioma: Results from an expanded access program in Germany. Respir. Med. 104:142-148. 2010.
Stahel, R., Baas, P., Faivre-Finn, C., Dooms, C., Passlick, B., Mazières, J., Cappuzzo, F., Früh, M., Sorensen, J.B., Blackhall, F., Taron, M., Gridelli, C., O’Byrne, K., Rosell, R. Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer 68:121-124. 2010.
Weder, W., Collaud, S., Eberhardt, W.E., Hillinger, S., Welter, S., Stahel, R., Stamatis, G., Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small cell lung cancer.J Thorac Cardiovasc Surg. J Thorac Cardiovasc Surg. 139:1424-30. 2010.
Samaras, P., Buset, E.M., Siciliano, R.D., Haile, S.R., Petrausch, U., Mischo, A., Honegger, H., Pestalozzi, B.C., Schanz, U., Stussi, G., Stahel, R.A., Knuth, A., Renner, C., Stenner-Liewen, F. Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation. Oncology. 79:93-97. 2010.
Martinelli, G., Schmitz, S.H., Utiger; U., Cerny, T., Hess, U., Bassi, S., Okkinga, E., Stupp, R., Stahel, R.A., Heizmann, M., Vorobiof, D., Lohri, A., Dietrich, P.Y., Zucca, E., Ghielmini, M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 28:4480-4. 2010.
Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., Dienemann, H., Galateau-Salle, F., Hennequin, C., Hillerdal, G., Le Péchoux, C., Mutti, L., Pairon, J.C., Stahel, R., van Houtte, P., van Meerbeeck, J., Waller, D., Weder, W. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of Malignant Pleural Mesothelioma. Eur. Respir. J. 35:479-495. 2010.
Pirker, R., Herth, F.J., Kerr, K.M., Filipits, M., Taron, M., Gandara, D., Hirsch, F.R., Grunenwald, D., Popper, H., Smit, E., Dietel, M., Marchetti, A., Manegold, C., Schirmacher, P., Thomas, M., Rosell, R., Cappuzzo, F., Stahel, R. European EGFR Workshop Group. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 5:1706-13. 2010.
Pavlidis, N., Gatzemeier, W., Popescu, R., Stahel, R., Pinedo, H., Cavalli, F., Costa, A. The masterclass of the european school of oncology: the ‚key educational event‘ of the school. Eur J Cancer. 46:2159-65. 2010.
Pavlidis, N., Hansen, H., Stahel, R. ESMO Clinical Practice Guidelines: development, implementation and dissemination. Ann Oncol. Suppl 5:v7-8. 2010.
Stahel, R.A., Weder, W., Lievens, Y., Felip, E. ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. Suppl 5:v126-8. 2010.
Collaud, S., Wiedl, T., Cattaneo, E:, Soltermann, A., Hillinger, S., Weder, W., Arni, S. Laser-Capture Microdissection Impairs Activity-Based Protein Profiles for Serine Hydrolase in Human Lung Adenocarcinoma. J Biomol Tech. 21:25–28. 2010.
2011
Sidi, R., Pasello, G., Opitz, I., Soltermann, A., Tutic, M., Rehrauer, H., Weder, W., Stahel, R.A., Felley-Bosco, E. Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis. European Journal of Cancer 47:326-332. 2011.*
Opitz I, Erne BV, Demirbas S, Jetter A, Seifert B, Stahel R, Weder W. Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study. J Thorac Cardiovasc Surg. 141:65-71. 2011.*
Frei, C., Opitz, I., Soltermann, A., Fischer, B., Moura, U., Rehrauer, H., Weder, W., Stahel , R., Felley-Bosco, E. Pleural mesothelioma side populations have a precursor phenotype and are similar to patient’s relapses. Carcinogenesis, 32:1324-32. 2011.*
Knobel, P.A., Kotov, I.N., Felley-Bosco, E., Stahel, R.A.,Marti, T.M. Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia 13:961-70. 2011.*
Surinova, S., Schiess, R., Hüttenhain, R., Cerciello, F., Wollscheid, B., Aebersold, R. On the development of plasma protein biomarkers. J Proteome Res. 10: 5-16. 2011.*
Knobel, P.A., Marti, T.M. Translesion DNA synthesis in the context of cancer research. Cancer Cell Int. 2;11:39. 2011.*
Felley-Bosco, E., Opitz, I., Soltermann, A., Thies, S., Weder, W., Stahel, R.. Asbestos-induced tissue regeneration and malignant pleural mesothelioma: insights from developmental studies. In: Advances in Medicine, Volume 34 ISBN 978-1-61470-009-8, Editor: Leon V. Berhardt, 131-153, Nova Science Publishers, Inc, 2011.*
Arbogast, S., Behnke, S., Opitz, I., Stahel, R.A., Seifert, B., Weder, W., Moch, H., Soltermann, A. Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297. Appl Immunohistochem Mol Morphol. 19:99-105. 2011.
Salazar, F., Molina, M.A., Sanchez-Ronco, M., Moran, T. Ramirez, J.L., Sanchez, J.M., Stahel, R., Garrido, P., Cobo, M., Isla, D., Bertran-Alamillo, J., Massuti, B., Cardenal, F., Manegold, C., Lianes, P., Trigo, J.M., Sanchez, J.J., Taron, M., Rosell, R. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer. 72:84-91. 2011.
Frauenfelder, T., Tutic, M., Weder, W., Götti, R.P., Stahel, R.A., Seifert, B., Opitz, I. Volumetry – an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J. 38:162-8. 2011.
Weder, W., Stahel, R.A., Baas, P., Dafni, U., de Perrot, M., McCaughan, B.C., Nakano, T., Pass, H.I., Robinson, B.W., Rusch, V.W., Sugarbaker, D.J., van Zandwijk, N. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 12:1093-4. 2011.
Gridelli, C., Stahel, R., Besse, B., Ciardiello, F., Felip, E., Gasparini, S., Graziano, P., Rossi, A., de Marinis, F. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer. 74:544-8. 2011.
von Boehmer, L., Draenert, A., Jungraithmayr, W., Inci, I., Niklaus, S., Boehler, A., Hofer, M., Stahel, R., Soltermann, A., van den Broek, M., Weder, W., Knuth, A. Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. Lung Cancer 76:118-22, 2011
Tischler, V., Pfeifer, M., Hausladen, S., Schirmer, U., Bonde, A-K., Kristiansen, G., Sos, M.L., Weder, W., Moch, H., Altevogt, P., Soltermann, A. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer 10:127. 2011.
Wagner, P.L., Stiedl, A.C., Wilbertz, T., Petersen, K., Scheble, V., Menon, R., Reischl, M., Mikut, R., Rubin, M.A., Fend, F., Moch, H., Soltermann, A., Weder, W., Altorki, N.K., Perner, S. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer 74:118-23. 2011.
Rice, D., Rusch, V., Pass, H., Asamura, H., Nakano, T., Edwards, J., Giroux, D.J., Hasegawa, S., Kernstine, K.H., Waller, D., Rami-Porta, R; International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 6:1304-12. 2011.
Stahel, R., Thatcher, N., Früh, M., Le Péchoux, C., Postmus, P.E., Sorensen, J.B., Felip, E; Panel members. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: Small-cell lung cancer. Ann Oncol. 22:1973-80. 2011.
Felip, E., Gridelli, C., Baas, P., Rosell, R., Stahel, R.; Panel Members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol. 22:1507-19. 2011.
2012
Schaefer, N.G., Veit-Haibach, P., Soyka, J.D., Steinert, H.C., Stahel, R.A. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): Value of 18F-FDG-PET/CT. Eur J Radiol 81:19-25. 2012.
Wiedl, T., Collaud, S., Hillinger, S., Arni, S., Burgess, C., Kroll, W., Schraml, P., Soltermann, A., Moch, H., Weder, W. KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma. Cancer Genomics Proteomics 9:51-4. 2012.
Stahel, R. Biomarker testing in non-small cell lung cancer: to move forward with quality. Clin Transl Oncol. 14:321-2. 2012.
Scagliotti, G., Stahel, R.A., Rosell, R., Thatcher, N., Soria, J.C. ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development. Eur J Cancer. 48:961-73. 2012.
Gridelli, C., de Marinis, F., Di Maio, M., Ardizzoni, A., Belani, C.P., Cappuzzo, F., Ciardiello, F., Fidias, P., Paz-Ares, L., Perrone, F., Pirker, R., De Petris, L., Stahel, R. Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 76:269-79, 2012.
Brodowicz, T., Ciuleanu, T., Crawford, J., Filipits, M., Fischer, J.R., Georgoulias, V, Gridelli, C., Hirsch, F.R., Jassem, J., Kosmidis, P., Krzakowski, M., Manegold, C., Pujol, J.L., Stahel, R., Thatcher, N., Vansteenkiste, J., Minichsdorfer, C., Zöchbauer-Müller, S., Pirker, R., Zielinski, C.C.; for the Central European Cooperative Oncology Group (CECOG). Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Ann Oncol 34:1223-29, 2012.
Collaud, S., Lardinois, D., Tischler, V., Steinert, H.C., Stahel, R., Weder, W. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer. Eur J Cardiothorac Surg. 41:612-6. 2012.
Pavlidis, N, Vermorken, J.B., Stahel, R., Bernier, J., Cervantes, A., Pentheroudakis, G., Audisio, R., Costa, A. Undergraduate training in oncology: An ESO continuing challenge for medical students. Surg Oncol. 21:15-21. 2012.
Fischer, B., Frei, C., Moura, U, Stahel, R., Felley- Bosco, E. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy. Lung Cancer (im Druck).*
Storelli, E., Tutic, M., Kestenholz, P., Schneiter, D., Opitz, I., Hillinger, S., Weder, W. Sleeve resections with unprotected bronchial anastomoses are safe even after neoadjuvant therapy. (im Druck).
Thies, S., Opitz, I., Felley-Bosco, E., Mihic, D., Moch, H., Soltermann, A. Cancer stem cell markers of malignant pleural mesothelioma. (in Vorbereitung).